European Union - English - EMA (European Medicines Agency)

ipsen pharma - cabozantinib - thyroid neoplasms - antineoplastic agents - treatment of adult patients with progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma.

Canada - English - Health Canada

ipsen biopharmaceuticals canada inc - cabozantinib (cabozantinib malate) - tablet - 20mg - cabozantinib (cabozantinib malate) 20mg - antineoplastic agents

Canada - English - Health Canada

ipsen biopharmaceuticals canada inc - cabozantinib (cabozantinib malate) - tablet - 40mg - cabozantinib (cabozantinib malate) 40mg - antineoplastic agents

Canada - English - Health Canada

ipsen biopharmaceuticals canada inc - cabozantinib (cabozantinib malate) - tablet - 60mg - cabozantinib (cabozantinib malate) 60mg - antineoplastic agents

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

zuellig pharma sdn bhd - cabozantinib (s)-malate -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

zuellig pharma sdn bhd - cabozantinib (s)-malate -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

zuellig pharma sdn bhd - cabozantinib (s)-malate -

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

ipsen ltd - cabozantinib s-malate - tablet - 20mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

ipsen ltd - cabozantinib s-malate - tablet - 40mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

ipsen ltd - cabozantinib s-malate - tablet - 60mg